The Evolut Low Risk Trial: Self-expanding TAVR noninferior to surgery in low-risk patients
1. Among patients with severe aortic stenosis at low-risk for surgery, transcatheter aortic valve replacement (TAVR) with a self-expanding valve...
The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure
1. Among patients hospitalized for acute decompensated heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduced N-terminal pro-B...
RNA interference agent givosiran appears safe in phase I trial
1. Among patients with acute intermittent porphyria (AIP), there was no difference in the proportion of any and serious adverse...
Dapagliflozin associated with reduced hospitalization rate for heart failure
1. Among patients with type 2 diabetes and established or multiple risk factors for cardiovascular disease (CVD), dapagliflozin was noninferior...
The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease
1. During an 80-week trial period of patient’s with early Parkinson’s disease (PD), there was no difference in the severity...
The REGROUP trial: endoscopic and open vein-graft harvest associated with similar outcomes
1. Among patients randomized to an open or endoscopic vein-graft harvest technique for coronary-artery bypass graft (CABG) surgery, there was...
The REACH trial: hydroxyurea safe and effective for sickle cell anemia in African children
1. Among sub-Saharan African children with sickle cell anemia (SCA) treated with hydroxyurea, 5.1% experienced dose-limiting toxic events, well below...
Neither haloperidol nor ziprasidone significantly shortens delirium in the ICU
1. Among critically ill patients with delirium in the intensive care unit (ICU), there was no significant difference in the...
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared...
MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial
1. Among patients with heart failure with reduced ejection fraction (HFrEF) and severe secondary mitral regurgitation on medical therapy, percutaneous...